ABVD in the treatment of Hodgkin's disease

Valeria Bonfante, Armando Santoro, Simonetta Viviani, Pinuccia Valagussa, Gianni Bonadonna

Research output: Contribution to journalArticle

Abstract

This paper summarizes the clinical results achieved at the Milan Cancer Institute in advanced Hodgkin's disease through successive randomized studies performed during the last two decades. Long-term results confirm the therapeutic activity of a regimen containing bleomycin and doxorubicin, such as ABVD (doxorubicin/bleomycin/ vinblastine/dacarbazine), as salvage treatment and as primary chemotherapy, either when combined with radiation or cyclically alternated with MOPP (mechlorethamine/ vincristine/procarbazine/prednisone). Delayed iatrogenic morbidity (namely, sterility and leukemogenesis) was less frequently documented in ABVD-treated patients compared with MOPP-treated patients. Nevertheless, bleomycin- and anthracycline-containing regimens can be refined in the attempt to further decrease iatrogenic toxicity.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalSeminars in Oncology
Volume19
Issue number2 SUPPL. 5
Publication statusPublished - 1992

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Bonfante, V., Santoro, A., Viviani, S., Valagussa, P., & Bonadonna, G. (1992). ABVD in the treatment of Hodgkin's disease. Seminars in Oncology, 19(2 SUPPL. 5), 38-45.